Abstract
Guideline-based management of asthma was developed as a means of standardizing asthma therapies and of improving outcomes. The National Asthma Education and Prevention Program and the Global Initiative for Asthma guidelines provide recommendations to care providers about the routine management of asthma. There has been rapid development of new therapies for asthma, specifically with the advent of new drug delivery devices and biologic therapies for severe asthma. We are increasingly recognizing that asthma is a heterogenous disease with a diverse underlying pathophysiology, and therefore, it is imperative for care providers to begin to understand asthma phenotypes and endotypes, and the implications of these classifications on management, especially of severe refractory asthma. This article serves as a review of guideline-based therapy for asthma and includes updates on alternative therapies, new approaches that use previously recognized therapies, and special populations with asthma.
Footnotes
- Correspondence: Njira L Lugogo MD, 300 North Ingalls St Suite 2C40, Ann Arbor, MI 48109-5400. E-mail: nlugogo{at}umich.edu.
Dr Lugogo discloses relationships with Sanofi, AstraZeneca, GlaxoSmithKline, Merck, and Teva. Dr Meghdadpour has disclosed no conflicts of interest.
Dr Lugogo presented a version of this paper at the 56th Respiratory Care Journal Conference, Respiratory Medications for COPD and Adult Asthma: Pharmacologic Actions to Clinical Applications, held June 22–23, 2017 in St Petersburg, Florida.
- Copyright © 2018 by Daedalus Enterprises